Efficacy News and Research

RSS

Study analyzes effects of antidepressant drugs on well-being in children and adolescents

In an article published in the current issue of Psychotherapy and Psychosomatics the effects of antidepressant drugs on well-being in children and adolescents are analyze.

7 Jul 2014

Study analyzes difference between day hospital and inpatient stay in depression

A study published in the current issue of Psychotherapy and Psychosomatics has analyzed the difference between day hospital and inpatient stay in depression.

7 Jul 2014

Multicenter trial aims to find safety, effectiveness of probiotics in infants with stomach flu

Consumers worldwide spend billions of dollars each year on probiotic foods and supplements. But studies evaluating probiotics - microorganisms believed to aid digestive health - have been limited.

4 Jul 2014

Loss of p62 protein in cells and tissue surrounding a tumor can influence tumor growth

A team of scientists from Sanford Burnham Medical Research Institute has found that the loss of a protein called p62 in the cells and tissue surrounding a tumor can enhance the growth and progression of tumors.

4 Jul 2014

FDA grants Fast Track designation to Akashi Therapeutics' HT-100 for treatment of DMD

Akashi Therapeutics, Inc., announced today that the U.S. Food and Drug Administration has granted Fast Track designation to the company's most advanced product candidate, HT-100 (delayed-release halofuginone), an orally available, small molecule drug candidate intended to reduce fibrosis and inflammation and promote healthy muscle regeneration in boys with DMD.

3 Jul 2014

Analysis of clinical trials reveals urgent need to increase Alzheimer's drug development

Researchers at the Cleveland Clinic Lou Ruvo Center for Brain Health have conducted the first-ever analysis of clinical trials for Alzheimer's disease (AD), revealing an urgent need to increase the number of agents entering the AD drug development pipeline and progressing successfully towards new therapy treatments.

3 Jul 2014

Forest Laboratories completes acquisition of Furiex Pharmaceuticals

Actavis plc today announced that its subsidiary Forest Laboratories, LLC has successfully completed its acquisition of Furiex Pharmaceuticals, Inc. in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.

2 Jul 2014

Researchers identify new biomarker that predicts effectiveness of glioblastoma treatment

Researchers at the University of California, San Diego School of Medicine have identified a new biomarker that predicts whether glioblastoma - the most common form of primary brain cancer - will respond to chemotherapy. The findings are published in the July print issue of Oncotarget.

2 Jul 2014

Drug everolimus fails to improve overall survival in advanced liver cancer patients

Despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo, according to a study in the July 2 issue of JAMA.

2 Jul 2014

New way to combat bacterial biofilm formation with titanium encrusted with gold nanoparticles

Bacteria love to colonize surfaces inside your body, but they have a hard time getting past your rugged, salty skin.

1 Jul 2014

New smartphone-based system detects changes in patients' behavioral patterns

Mental illness accounts for 90 percent of all reported suicides and places the largest burden of any disease on social and economic infrastructures worldwide, according to the World Health Organization.

1 Jul 2014

Vitreous anatomic features characterised

Researchers have found a direct anteroposterior connection between the retrolental and premacular and preoptic spaces that exits in young adults before the occurrence of vitreous degeneration.

1 Jul 2014

CTI completes recruitment in PERSIST-1 clinical trial of pacritinib for treatment of myelofibrosis

CTI BioPharma Corp. announced today that it has completed recruitment in the PERSIST-1 pivotal Phase 3 clinical trial of pacritinib, a novel oral JAK2/FLT3 inhibitor that is being evaluated for the treatment of myelofibrosis.

From Baxter International Inc. 1 Jul 2014

Herbal supplement can become dangerous when taken with prescribed drugs

St. John's wort, the leading complementary and alternative treatment for depression in the United States, can be dangerous when taken with many commonly prescribed drugs, according to a study by researchers at Wake Forest Baptist Medical Center.

1 Jul 2014

Aclaris Therapeutics reports positive results from A-101 Phase 2 trial for removing SK lesions

Aclaris Therapeutics, Inc. today announced positive results from a Phase 2 clinical trial of the Company's lead drug, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing seborrheic keratoses (SK), one of the most common types of skin tumors.

1 Jul 2014

BioLight enrolls first patient in FDA Phase 1/2a clinical trial with Eye-D for treatment of glaucoma

BioLight Israeli Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces that the first patient has been enrolled in the U.S. into a FDA Phase 1/2a clinical trial with Eye-D, the company's controlled-release latanoprost insert for the treatment of glaucoma.

1 Jul 2014

Genetic variants alter chance of sunitinib dose reduction

Scientists have identified genetic variants that reduce the likelihood of sunitinib dose reduction in patients with metastatic renal cell carcinoma.

30 Jun 2014

FSC Laboratories acquires exclusive marketing rights for Aciphex Sprinkle in the U.S.

FSC Therapeutics, LLC, today announced that the Company has entered into a transaction with Eisai Inc. to acquire exclusive U.S. marketing rights for AcipHex® Sprinkle™ (rabeprazole sodium), Delayed-Release Capsules, 5 mg and 10 mg, for the treatment of Gastroesophageal Reflux Disease (GERD) in children 1 to 11 years of age for up to 12 weeks.

30 Jun 2014

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Merck, known as MSD outside the United States and Canada, today announced results from a global, investigational Phase 3 study to evaluate the safety and efficacy of EMEND (aprepitant) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric cancer patients, aged 6 months to 17 years.

30 Jun 2014

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY), announced today that Argentina's National Administration of Drugs, Food and Medical Technology (ANMAT) has approved LemtradaTM (alemtuzumab) for adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.

30 Jun 2014

Efficacy News and Research

Study analyzes effects of antidepressant drugs on well-being in children and adolescents

Study analyzes difference between day hospital and inpatient stay in depression

Multicenter trial aims to find safety, effectiveness of probiotics in infants with stomach flu

Loss of p62 protein in cells and tissue surrounding a tumor can influence tumor growth

FDA grants Fast Track designation to Akashi Therapeutics' HT-100 for treatment of DMD

Analysis of clinical trials reveals urgent need to increase Alzheimer's drug development

Forest Laboratories completes acquisition of Furiex Pharmaceuticals

Researchers identify new biomarker that predicts effectiveness of glioblastoma treatment

Drug everolimus fails to improve overall survival in advanced liver cancer patients

New way to combat bacterial biofilm formation with titanium encrusted with gold nanoparticles

New smartphone-based system detects changes in patients' behavioral patterns

Vitreous anatomic features characterised

CTI completes recruitment in PERSIST-1 clinical trial of pacritinib for treatment of myelofibrosis

Herbal supplement can become dangerous when taken with prescribed drugs

Aclaris Therapeutics reports positive results from A-101 Phase 2 trial for removing SK lesions

BioLight enrolls first patient in FDA Phase 1/2a clinical trial with Eye-D for treatment of glaucoma

Genetic variants alter chance of sunitinib dose reduction

FSC Laboratories acquires exclusive marketing rights for Aciphex Sprinkle in the U.S.

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News